Sugi Predict

Sugi Predict / Compounds / SCHEMBL29440046

SCHEMBL29440046

SCHEMBL29440046

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.77

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CRHR1 P34998 1/20 0.77
▸ CRHR2 Q13324 1/20 0.77
▸ CALCR P30988 4/20 0.73
▸ HCRTR1 O43613 1/20 0.68
▸ HCRTR2 O43614 1/20 0.68
▸ F2 P00734 4/20 0.66
▸ NPY2R P49146 6/20 0.62
▸ NPY4R P50391 6/20 0.62
▸ NPY5R Q15761 6/20 0.62
▸ NPY1R P25929 4/20 0.62
▸ CCKBR P32239 2/20 0.61
▸ GLP1R P43220 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Neuropeptide Y(Npy) SCHEMBL29557110 0.93 HCRTR1 (0.73) CRHR1CRHR2CALCRHCRTR1HCRTR2
SCHEMBL29351932 0.93 CRHR1 (0.74) CRHR1CRHR2CALCRHCRTR1HCRTR2
Human Neuropeptide Y SCHEMBL29523348 0.92 CALCR (0.72) CRHR1CRHR2CALCRNPY2RNPY4R
Human Neuropeptide Y SCHEMBL29523253 0.92 NPY2R (0.70) CRHR1CRHR2CALCRNPY2RNPY4R
SCHEMBL31362091 0.91 CRHR1 (0.69) CRHR1CRHR2CALCRHCRTR1HCRTR2
Neuropeptide-Y SCHEMBL31042464 0.89 NPY2R (0.73) CRHR1CRHR2CALCRHCRTR1HCRTR2
SCHEMBL30658230 0.89 CALCR (0.79) CRHR1CRHR2CALCRHCRTR1HCRTR2
SCHEMBL30932076 0.88 CALCR (0.82) CRHR1CRHR2CALCRHCRTR1HCRTR2
SCHEMBL29379306 0.88 F2 (0.78) CRHR1CRHR2CALCRHCRTR1HCRTR2
SCHEMBL29767110 0.88 CALCR (0.82) CRHR1CRHR2CALCRHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260147005-A1 BIOMARKER FOR DIAGNOSIS, PROGNOSIS, ASSESSMENT AND THERAPY STRATIFICATION THE UNIVERSITY OF MELBOURNE (AU) 2026-05-28 — — US disclosed
EP-4199925-B1 CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-05-20 — — EP disclosed
US-12552767-B2 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists MERCK SHARP & DOHME LLC (US) 2026-02-17 — — US disclosed
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
EP-3924058-B1 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-07 — — EP disclosed
US-12497362-B2 Cyclopentapyrrole orexin receptor agonists MERCK SHARP & DOHME LLC (US) 2025-12-16 — — US disclosed
EP-4640701-A2 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF Janssen Sciences Ireland Unlimited Company (IE) 2025-10-29 — — EP disclosed
EP-4618974-A1 OREXIN RECEPTOR AGONISTS Merck Sharp & Dohme LLC (US) 2025-09-24 — — EP disclosed
US-20250282760-A1 OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2025-09-11 — — US disclosed
EP-3784692-B1 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2025-08-27 — — EP disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 — — WO disclosed
EP-4010314-A1 HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2022-06-15 — — EP disclosed
WO-2022119888-A1 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-09 — — WO disclosed
WO-2022109117-A1 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-05-27 — — WO disclosed
US-20220144771-A1 PYRROLIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-05-12 — — US disclosed
WO-2022094012-A1 MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-05-05 — — WO disclosed
EP-3988123-A1 ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS Janssen Pharmaceutica NV (BE) 2022-04-27 — — EP disclosed
WO-2022040058-A1 CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-02-24 — — WO disclosed
WO-2022040070-A1 BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-02-24 — — WO disclosed
US-20220056017-A1 BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497362-B2 Cyclopentapyrrole orexin receptor agonists HCRTR2, HCRTR1, NPY1R CRHR1 5/4885CRHR2 9/4885CALCR 375/4885
US-12552767-B2 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists HCRTR2, HCRTR1, NPY1R CRHR1 6/4885CRHR2 9/4885CALCR 468/4885
US-20260147005-A1 BIOMARKER FOR DIAGNOSIS, PROGNOSIS, ASSESSMENT AND THERAPY STRATIFICATION NPY1R, BDNF, NGF CRHR1 67/4885CRHR2 98/4885CALCR 45/4885
US-20220056017-A1 BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS HCRTR1, HCRTR2, CRHR1 CRHR1 3/4885CRHR2 4/4885CALCR 239/4885
US-20250282760-A1 OREXIN RECEPTOR AGONISTS HCRTR2, HCRTR1, OXTR CRHR1 4/4885CRHR2 6/4885CALCR 236/4885
US-20220144771-A1 PYRROLIDINE OREXIN RECEPTOR AGONISTS HCRTR2, HCRTR1, OXTR CRHR1 4/4885CRHR2 5/4885CALCR 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback